<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3367">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01395966</url>
  </required_header>
  <id_info>
    <org_study_id>DF289III/10IA02</org_study_id>
    <nct_id>NCT01395966</nct_id>
  </id_info>
  <brief_title>Clinical Study to Assess the Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients</brief_title>
  <official_title>Clinical Study to Assess the Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Salvat</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Salvat</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Spain: Agencia Espa√±ola de Medicamentos y Productos Sanitarios</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>South Africa: Medicines Control Council</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Denmark: Danish Medicines Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the combination of DF289 plus DF277 is safe and
      effective in treating middle ear infections in children with ear tubes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to Cessation of Otorrhea</measure>
    <time_frame>From baseline until the end of the study ( up to 22 days)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">331</enrollment>
  <condition>Acute Otitis Media</condition>
  <arm_group>
    <arm_group_label>DF289</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ear drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DF277</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ear drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DF289 plus DF277</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ear drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DF289</intervention_name>
    <description>Ear drops</description>
    <arm_group_label>DF289</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DF277</intervention_name>
    <description>Ear drops</description>
    <arm_group_label>DF277</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DF289 plus DF277</intervention_name>
    <description>Ear drops</description>
    <arm_group_label>DF289 plus DF277</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  6 months to 12 years

          -  ear tube in the ear which will be treated

          -  otorrhea for 3 weeks or less

          -  moderate or severe otorrhea

        Exclusion Criteria:

          -  other ear diseases
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Laboratorios Salvat, S.A.</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 22, 2015</lastchanged_date>
  <firstreceived_date>July 8, 2011</firstreceived_date>
  <firstreceived_results_date>July 22, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>with tubes</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Media</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>DF289</title>
          <description>Ear drops
DF289: Ear drops</description>
        </group>
        <group group_id="P2">
          <title>DF277</title>
          <description>Ear drops
DF277: Ear drops</description>
        </group>
        <group group_id="P3">
          <title>DF289 Plus DF277</title>
          <description>Ear drops
DF289 plus DF277: Ear drops</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="110"/>
                <participants group_id="P3" count="112"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="91"/>
                <participants group_id="P3" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DF289</title>
          <description>Ear drops
DF289: Ear drops</description>
        </group>
        <group group_id="B2">
          <title>DF277</title>
          <description>Ear drops
DF277: Ear drops</description>
        </group>
        <group group_id="B3">
          <title>DF289 Plus DF277</title>
          <description>Ear drops
DF289 plus DF277: Ear drops</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="109"/>
                <measurement group_id="B2" value="110"/>
                <measurement group_id="B3" value="112"/>
                <measurement group_id="B4" value="331"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>randomized patients</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="109"/>
                <measurement group_id="B2" value="110"/>
                <measurement group_id="B3" value="112"/>
                <measurement group_id="B4" value="331"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="3.5" spread="2.7"/>
                <measurement group_id="B2" value="3.5" spread="2.6"/>
                <measurement group_id="B3" value="3.2" spread="2.5"/>
                <measurement group_id="B4" value="3.4" spread="2.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>randomized patients</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="66"/>
                <measurement group_id="B2" value="68"/>
                <measurement group_id="B3" value="64"/>
                <measurement group_id="B4" value="198"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="43"/>
                <measurement group_id="B2" value="42"/>
                <measurement group_id="B3" value="48"/>
                <measurement group_id="B4" value="133"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Cessation of Otorrhea</title>
        <time_frame>From baseline until the end of the study ( up to 22 days)</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>DF289</title>
            <description>Ear drops
DF289: Ear drops</description>
          </group>
          <group group_id="O2">
            <title>DF277</title>
            <description>Ear drops
DF277: Ear drops</description>
          </group>
          <group group_id="O3">
            <title>DF289 Plus DF277</title>
            <description>Ear drops
DF289 plus DF277: Ear drops</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="109"/>
                  <measurement group_id="O2" value="110"/>
                  <measurement group_id="O3" value="112"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Cessation of Otorrhea</title>
            <units>days</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7.69" lower_limit="4.78" upper_limit="11.44"/>
                  <measurement group_id="O2" value="22" lower_limit="7.43" upper_limit="22"/>
                  <measurement group_id="O3" value="3.75" lower_limit="3.04" upper_limit="4.39"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During all the study (22 days)</time_frame>
      <desc>Only related TEAE are reported. There were 331 patients randomized, but only 327 were dosed. Only dosed patients are considered for the AE Reporting.
One patient was randomized to receive DF277 but began taking DF289 Plus DF277. This patient is included in the safety population under DF289 Plus DF277 treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>DF289</title>
          <description>Ear drops
DF289: Ear drops</description>
        </group>
        <group group_id="E2">
          <title>DF277</title>
          <description>Ear drops
DF277: Ear drops</description>
        </group>
        <group group_id="E3">
          <title>DF289 Plus DF277</title>
          <description>Ear drops
DF289 plus DF277: Ear drops</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>auricular swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>otorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>ear canal erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>ear discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>ear haemorrahage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>otitis media acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>ear infection fungal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>otitis externa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>excessive granulation tissue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor does not object to publication by Institution of the results of the Trial based on information collected or generated by Institution, whether or not the results are favorable to the Sponsor Drug. However, to ensure against inadvertent disclosure of Confidential Information or unprotected Inventions, Institution will provide Sponsor an opportunity to review any proposed publication or other type of disclosure before it is submitted or otherwise disclosed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Enrique Jimenez, Medical Director</name_or_title>
      <organization>Laboratorios SALVAT</organization>
      <phone>+34933946470</phone>
      <email>ejimenezv@salvatbiotech.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
